EANS-News: SYGNIS announces three months results of fiscal year 2010/2011

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

3-month report

Heidelberg (euro adhoc) - Press release

Heidelberg, August 12, 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN
DE0005043509; Prime Standard) today reports financial results for the first
quarter of the fiscal year 2010/2011 ended June 30, 2010.

Financials

• Cash including marketable securities amounted to EUR13.1 million as of
June 30, 2010 (EUR19.4 million Q1 2009/2010). Long term financial
liabilities amounted to EUR8.0 million resulting from a loan which is not
due for repayment before 2015.

• Total operating expenses for the quarter was EUR2.5 million, which was
the same as the first three months of 2009/2010.

• The net loss in the first quarter was EUR-2.3 million, which was
the same as the previous year.

Milestones

• Patient recruitment for the phase II efficacy study of the Company´s lead
compound AX200, for the treatment of acute ischemic stroke, has
significantly increased following the implementation of the modification
of the AXIS 2 study protocol.
• At its first meeting on 2 August 2010, the Data Safety Monitoring Board
(DSMB) reviewed the data on the safety and tolerability of the AXIS 2
study medication and advised on the continuation of the study without
changes.

Outlook

SYGNIS confirms its expectations of a net loss of around EUR15
million for the current 2010/2011 fiscal year and a liquidity
outflow of some EUR14 million.

Due to the modification to the AXIS 2 study protocol and the
acceleration of patient recruitment, the Company expects to present
its initial findings of the study by mid-2011.

In addition the Company continues to evaluate opportunities to
extend its product pipeline and is working towards concluding a
research alliance for the KIBRA project.

|Key financial figures for the first quarter of fiscal year |
|2010/2011 ended June 30, 2010 and corresponding figures (IFRS) |
|Numbers in million euros |Q1 2010/2011 |Q1 2009/2010 |
|Revenues |0.1 |0.0 |
|Total expenses |2.5 |2.5 |
|EBIT |-2.4 |-2.4 |
|Net results for the period |-2.3 |-2.3 |
|Intangible assets |21.8 |22.2 |
|Liquidity at end of quarter |13.1 |19.4 |
|Equity |27.7 |34.1 |
|(equity ratio in %) |(69) |(72) |
|Long-term financial liabilities |8.0 |8.0 |
|Operating Cash Flow |-2.3 |-3.0 |

The report on the first quarter which ended on June 30, 2010 is
available at the SYGNIS webpage at www.sygnis.de.

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,
is a specialty pharmaceutical company listed on the Prime Standard
of the German stock exchange. The Company is focused on the
research, development and marketing of innovative therapies for
the treatment of disorders of the Central Nervous System. These
include Stroke, Amyotrophic Lateral Sclerosis and neurological
disorders resulting from injuries to the brain or spinal cord. All
these disorders are characterized by the fact that, as the disease
progresses, nerve cells are damaged and die. Although there is
great medical demand, there are currently no or only
inadequate treatment options available.

One of the central elements in this value-creation chain is the
continued expansion of the existing product pipeline. This is
achieved by the development of new products as a result of SYGNIS´
own research and the inorganic growth through in-licensing
agreements and acquisitions. By means of specific R&D programs
at SYGNIS, new pre-clinical drug candidates are identified
and evaluated as well as preclinical projects initiated, which
are offered for inlicensing.

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

For further information please contact:

SYGNIS Pharma AG:

|Dr. Franz-Werner Haas |

|Vice President Operations |

|+49 (0) 6221 454 812 |

|franz-werner.haas@sygnis.de |

Media-Contact:

Julia Phillips

Financial Dynamics

Tel.: +44 (0) 20 7269 7187

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade